Skip to main navigation
Skip to search
Skip to main content
Pure University (For Demo Only) Home
Help & FAQ
English
中文
Home
Profiles
Research units
Research output
Equipment
Datasets
Activities
Prizes
Impacts
Projects
Press/Media
Search by expertise, name or affiliation
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
Research output
:
Contribution to journal
›
Article
›
peer-review
18
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Scotland
100%
Thrombocytopenia
100%
Hemorrhagic Disease
100%
ChAdOx1
100%
BNT162b2 COVID-19 Vaccine
100%
Second Dose
100%
Thrombotic Thrombocytopenic Purpura
50%
Confidence Interval
37%
Incidence Rate
37%
Risk Periods
25%
BNT162b2
25%
Vaccination
12%
Risk Profile
12%
Further Analysis
12%
Case Series Analysis
12%
Self-controlled Case Series
12%
BNT162b2 Vaccine
12%
ChAdOx1 Vaccine
12%
Reassurance
12%
Two-dose
12%
Pharmacology, Toxicology and Pharmaceutical Science
Thromboembolism
100%
COVID-19 Vaccine
100%
Idiopathic Thrombocytopenic Purpura
100%
Vaccination Policy
50%
Biochemistry, Genetics and Molecular Biology
Reassurance
25%